搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

  1. 首頁
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human Transmembrane glycoprotein NMB(GPNMB) ELISA kit

Human Transmembrane glycoprotein NMB(GPNMB) ELISA kit

  • 中文名稱：
    人跨膜糖蛋白NMB(GPNMB)酶聯(lián)免疫試劑盒
  • 貨號：
    CSB-EL009727HU-IS
  • 規(guī)格：
    96T/48T
  • 價(jià)格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    人跨膜糖蛋白NMB(GPNMB)酶聯(lián)免疫試劑盒（CSB-EL009727HU-IS）為雙抗夾心法ELISA試劑盒，定量檢測血清、血漿、組織勻漿、組織培養(yǎng)上清液樣本中的GPNMB含量。GPNMB是一個(gè)值得關(guān)注的靶點(diǎn)。其在多種生理和病理過程中發(fā)揮作用，比如參與腫瘤的發(fā)生發(fā)展等。研究機(jī)制上主要聚焦于其在細(xì)胞內(nèi)信號傳導(dǎo)、促進(jìn)腫瘤細(xì)胞增殖與遷移等方面，圍繞它有望開發(fā)新的診斷標(biāo)志物和治療靶點(diǎn)。試劑盒檢測范圍為0.156 ng/mL-10 ng/mL，靈敏度為0.039 ng/mL。該產(chǎn)品適用于腫瘤發(fā)生機(jī)制研究、藥物靶點(diǎn)篩選、疾病模型中的蛋白表達(dá)動態(tài)監(jiān)測等科研場景，特別針對腫瘤微環(huán)境調(diào)控、細(xì)胞遷移實(shí)驗(yàn)等研究方向提供定量分析支持。本品僅用于科研，不用于臨床診斷，產(chǎn)品具體參數(shù)及操作步驟詳見產(chǎn)品說明書。
  • 別名：
    Glycoprotein (transmembrane) nmb ELISA Kit; Glycoprotein nmb ELISA Kit; Glycoprotein nmb like protein ELISA Kit; Gpnmb ELISA Kit; GPNMB_HUMAN ELISA Kit; HGFIN ELISA Kit; NMB ELISA Kit; Osteoactivin ELISA Kit; Transmembrane glycoprotein ELISA Kit; Transmembrane glycoprotein HGFIN ELISA Kit; Transmembrane glycoprotein NMB ELISA Kit
  • 縮寫：
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, tissue homogenates, cell culture supernates
  • 檢測范圍：
    0.156 ng/mL-10 ng/mL
  • 靈敏度：
    0.039 ng/mL
  • 反應(yīng)時(shí)間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測波長：
    450 nm
  • 研究領(lǐng)域：
    Cancer
  • 測定原理：
    quantitative
  • 測定方法：
    Sandwich
  • 精密度：

    Intra-assay Precision (Precision within an assay): CV%<8%

    Three samples of known concentration were tested twenty times on one plate to assess.

    Inter-assay Precision (Precision between assays): CV%<10%

    Three samples of known concentration were tested in twenty assays to assess.

  • 線性度：

    To assess the linearity of the assay, samples were spiked with high concentrations of human GPNMB in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.

    　

    Sample

    Serum(n=4)

    1:1

    Average %

    95

    Range %

    88-101

    1:2

    Average %

    101

    Range %

    94-107

    1:4

    Average %

    98

    Range %

    92-105

    1:8

    Average %

    92

    Range %

    85-98

  • 回收率：

    The recovery of human GPNMB spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

    Sample Type

    Average % Recovery

    Range

    Serum (n=5)

    90

    84-97

    EDTA plasma (n=4)

    96

    90-102

  • 標(biāo)準(zhǔn)曲線：

    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

    ng/ml

    OD1

    OD2

    Average

    Corrected

    10

    2.719

    2.634

    2.677

    2.514

    5

    2.069

    1.947

    2.008

    1.846

    2.5

    1.275

    1.228

    1.252

    1.090

    1.25

    0.743

    0.729

    0.736

    0.574

    0.625

    0.519

    0.521

    0.520

    0.358

    0.312

    0.349

    0.333

    0.341

    0.179

    0.156

    0.239

    0.244

    0.242

    0.080

    0

    0.164

    0.160

    0.162

    　

  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評價(jià)

靶點(diǎn)詳情

  • 功能：
    Could be a melanogenic enzyme.
  • 基因功能參考文獻(xiàn)：
    1. loss of GPNMB, which has been implicated in melanosome formation, autophagy, phagocytosis, tissue repair, and negative regulation of inflammation, underlies autosomal-recessive Amyloidosis cutis dyschromica. PMID: 29336782
    2. Study shows high GPNMB mRNA level in osteosarcoma tissues and cell lines. Its silencing regulates the proliferation and metastasis of osteosarcoma cells by suppressing the PI3K/Akt/mTOR signaling pathway. PMID: 29620278
    3. Serum levels of GPNMB were highly correlated with accumulation of bioactive lipid substrate of Gaucher disease, glucosylsphingosine as well as established biomarkers, chitotriosidase and chemokine, CCL18. PMID: 28003098
    4. Increased brain expression of GPNMB is associated with genome wide significant risk for Parkinson's disease PMID: 28391543
    5. This study revealed that GPNMB aggregates are localized to the neuron, and not localized to the astrocyte and microglia and in the spinal cord of ALS patients. GPNMB has protective effects against mutant TDP-43-induced motor neuron cell death, via ERK1/2 and Akt pathway.. PMID: 27935101
    6. This review will summarize the latest understanding of Gpnmb in the aspects of diagnosis, progression and prognosis of pathological disorders and neoplasms, emphasizing the clinical advances in targeting Gpnmb-expressing malignancies--{REVIEW} PMID: 29441921
    7. The combination of MAPK pathway inhibitors with an antibody-drug conjugate targeting GPNMB is an effective therapeutic option. PMID: 27515299
    8. High GPNMB expression is associated with enhancement of invasive behavior in lung cancer. PMID: 26883195
    9. Findings suggest that MAFK and its target gene GPNMB play important roles in the malignant progression of triple-negative breast cancer (TNBC) cells, offering potentially new therapeutic targets for TNBC patients. PMID: 28400538
    10. glycoprotein non-metastatic B presented increased expression in breast cancer in vivo compared to normal breast tissue PMID: 28689015
    11. Osteoactivin differential regulates the expression of matrix metalloproteases in head and neck squamous cell carcinomas to promote cancer cell invasion. PMID: 28295306
    12. The GPNMB is expressed in a temporal manner during eosinophil development and delivers a proliferative signal upon activation. PMID: 28104809
    13. it may be premature to conclude associations between GPNMB rs156429 and Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy. PMID: 27132081
    14. Glycoprotein nonmetastatic melanoma protein B protein was highly expressed in the bladder cancer, which was related to the poor prognosis in bladder cancer patients. Glycoprotein nonmetastatic melanoma protein B promoted the proliferation, migration, and invasion in bladder cancer cells. PMID: 28443476
    15. an inducer for glioma and could enhance matrix metalloproteinase activity through Wnt/beta-catenin pathway to contribute to glioma tumorigenesis PMID: 27334625
    16. findings indicate that GPNMB promotes glioma growth via Na(+)/K(+)-ATPase alpha subunits. Thus, the interaction between GPNMB and Na(+), K(+)-ATPase alpha subunits represents a novel therapeutic target for the treatment of brain glioblastomas. PMID: 27836549
    17. Finally, we identify glycoprotein NMB as a melanocytic marker up-regulated in Tsc2-null mouse uteri and human lymphangioleiomyomatosis samples PMID: 26880751
    18. The GPNMB is a promising biomarker and therapeutic target for the development and progression of Nonalcoholic fatty liver disease in obesity. PMID: 26581806
    19. Osteoactivin in the extracellular matrix promotes oral squamous carcinoma cell adhesion and migration. PMID: 26636434
    20. Gpnmb Is a Potential Marker for the Visceral Pathology in Niemann-Pick Type C Disease PMID: 26771826
    21. GPNMB might be a surrogate marker for BC and may cross talk with the HER2 signal pathway. PMID: 26077887
    22. GPNMB plays an important roles in regulating the expression of key pluripotency genes in dental pulp cells and modifying odontogenic differentiation. PMID: 26261527
    23. A positive correlation between GPNMB and NRP-1 levels in human breast tumors. PMID: 25772243
    24. Data shows that the expression of Gpnmb and Spp1 is highly upregulated in glioma-associated microglia/macrophages highlighting the importance of macrophages and microglia as therapeutic targets in anti-tumor treatment regimens. PMID: 25658639
    25. GPNMB/OA protein expression prevents cells from apoptosis-enhancing proliferation and represents a novel modulator of the invasion and metastasis in pancreatic cancer cells. PMID: 25426614
    26. The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells. PMID: 25889792
    27. GPNMB mRNA in FLCN-related renal cell carcinomas was 23-fold more abundant than in sporadic tumors. PMID: 25594584
    28. GPNMB has protective effect against ischemia-reperfusion injury via phosphorylation of ERK1/2 and Akt PMID: 25010402
    29. Glycoprotein nonmetastatic melanoma protein B plays an important role in angiogenesis during hyperoxia injury PMID: 25054912
    30. DC-HIL+ CD14+ HLA-DR no/low cells are a potential blood marker and therapeutic target for melanoma PMID: 24933321
    31. Our data identify Gpnmb as a novel marker for obesity-induced adipose tissue macrophage infiltration and potentiator of interleukin-4 responses and point toward a crucial role for MITF in driving part of the adipose tissue macrophage phenotype. PMID: 24789918
    32. GPNMB/OA acts as a critical molecular mediator promoting the acquisition of the more aggressive, pro-metastatic phenotype distinctive of human DU145 and PC3 cell lines. PMID: 24589892
    33. our findings will clarify a new explanation about how GPNMB induces bone repair, and provide a potential target for bone regeneration therapeutics and bone engineering PMID: 23794283
    34. the molecular basis for the distinct trafficking and morphogenetic properties of PMEL and GPNMB is the PKD domain PMID: 23452376
    35. GPNMB expression was regulated by EpCAM and CSF-1 partly through their common downstream product c-myc PMID: 23924854
    36. Silencing of GPNMB by siRNA inhibits the formation of melanosomes in melanocytes in a MITF-independent fashion. PMID: 22912767
    37. GPNMB inhibits motor neuron death and plays a critical role in motor neuron survival. PMID: 22891158
    38. Together these results suggest that GPNMB gene is a p53- and androgen-dysregulated gene and should be regarded as an anti-tumor gene for prostate cancer. PMID: 22290289
    39. The abnormal expression of GPNMB may play an important role in the development of prostate cancer. PMID: 21844952
    40. Gastrointestinal stromal tumours do not show immunopositivity for ERa or HMB45. PMID: 22014058
    41. upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors PMID: 21874302
    42. GPNMB increase in kidney disease was confirmed by real-time PCR after 5/6 nephrectomy, in streptozotocin-induced diabetes, and in patients with chronic kidney disease PMID: 21389974
    43. Toxin-conjugated DC-HIL to abrogate the ability of Sezary syndrome cells to proliferate in vitro. PMID: 21252093
    44. ADAM10 as a sheddase capable of releasing the GPNMB/OA ectodomain from the surface of breast cancer cells PMID: 20711474
    45. GPNMB expression has a role in uveal melanoma PMID: 20375921
    46. GPNMB expression is associated with the basal/triple-negative subtype and is a prognostic marker of poor outcome in patients with breast cancer. PMID: 20215530
    47. GPNMB is a melanosomal protein that is released by proteolytic ectodomain shedding and might be a useful and specific histological marker of melanocytic cells. PMID: 20056711
    48. Human OA uses the same transcriptional initiation site in both bone and kidney as was reported for melanoma cells and is expressed in osteoblast cultures at all stages of differentiation PMID: 14696968
    49. cloning and analysis of two fragments in the 5' flanking region of HGFIN; studies indicate p53 cooperates with cytokine-mediated transcription factors to regulate the expression of HGFIN PMID: 15684612
    50. Osteoactivin is expressed at high levels in normal and inflammatory liver macrophages suggesting a significant role in acute liver injury. PMID: 15763343

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Glioblastoma multiforme patients that exhibit increased mRNA and protein levels (>3-fold over normal brain) in biopsy samples have a significantly higher risk of death (PubMed:16609006). In the context of cancer immunotherapy, including that of melanoma, has been proposed to be used as a cell surface protein antigen targeted by antibodies coupled to cytotoxic drugs (PubMed:16489096).
  • 亞細(xì)胞定位：
    Cell membrane; Single-pass type I membrane protein. Melanosome membrane; Single-pass type I membrane protein. Early endosome membrane; Single-pass type I membrane protein.
  • 蛋白家族：
    PMEL/NMB family
  • 組織特異性：
    Widely expressed, but very low expression, if any, in the brain. Expressed in the epidermis with higher levels in melanocytes compared with keratinocytes and Langerhans cells (at protein level). Expressed in peripheral blood, but not bone marrow mononucle
  • 數(shù)據(jù)庫鏈接：

    HGNC: 4462

    OMIM: 604368

    KEGG: hsa:10457

    STRING: 9606.ENSP00000371420

    UniGene: Hs.190495